Chugai Pharmaceutical Co Ltd
4519: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
JPY 2,825.00 | Cxzbp | Pyvpdzrq |
Chugai Earnings in Line, FVE Unchanged at JPY 4,860
Narrow-moat Chugai’s first quarter was in line with our expectations. Top-line revenue was JPY 169 billion, or 10% lower than the same period last year, mostly due to declines in Edirol and Actemra. Although progress for the year has started off slowly, with the JPY 167 million of revenue representing only 19% progress on our full-year forecast, this is within the usual range of fluctuation given the lumpiness of exports to Roche.